ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
Clinical trials for ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) trials appear
Sign up with your email to follow new studies for ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Last-Resort drug access opens for ALK-Positive cancer patients
Disease control AVAILABLEThis program offers early access to the investigational drug neladalkib for people with advanced ALK-positive lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial. Participants must be at least 18 years old…
Matched conditions: ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
Sponsor: Nuvalent Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Antidepressant may ease brain fog from lung cancer drug
Symptom relief Recruiting nowThis study tests whether vortioxetine, an antidepressant known to boost thinking skills, can reduce the mental fogginess caused by the lung cancer drug lorlatinib. About 24 adults with advanced ALK-positive lung cancer who are already taking lorlatinib will receive vortioxetine. …
Matched conditions: ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC